“…GHB was inferior to a benzodiazepine regimen regarding efficacy in hallucination control and metabolic side effects (Lenzenhuber et al., ) but still more potent than low‐dosed clomethiazol following Elsing's small RCT (Elsing et al., ). Even if some experts see it as an effective agent for AWS treatment in ICUs (Kleinschmidt and Mertzlufft, ; Meyer et al., ; Vagts et al., ) and our analyzed studies showed a sufficient effect especially for vegetative AWS symptoms, it has to be seen critically because of its toxicity (Lenzenhuber et al., ) and its hallucinatory side effect. Another important concern about GHB is its strong dependence potential, a reason why it is declared as a controlled substance in some countries, and it is not approved at all in some other countries.…”